Quarterly report pursuant to Section 13 or 15(d)

LIQUIDITY (Details)

v3.24.0.1
LIQUIDITY (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 14, 2023
Jan. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Jun. 30, 2023
Accumulated deficit     $ (289,418)   $ (289,418)   $ (260,985)
Net Income (Loss)     (13,909) $ (13,556) (28,433) $ (23,387) (51,800)
Net cash used in operating activities         (23,605) $ (15,082) (44,500)
Cash and cash equivalents     12,504   12,504   16,036
Short-term investments     80,094   80,094   85,860
Long-term investments     3,352   3,352   16,470
Total liabilities     10,422   10,422   7,549
Current liabilities     $ 8,008   8,008   $ 5,200
At the Market Offering              
Amount agreed to sell as per open market sales agreement $ 50,000            
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon First Dosing Of The First Patient [Member]              
Milestone closing payment   $ 5,000     5,000    
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient [Member]              
Milestone closing payment         $ 5,000